BEGIN YOUR JOURNEY TOWARDS PREVENTING CRYPTOGENIC STROKE

If you’ve had a stroke due to an unknown cause, learn how you may be able to prevent another with the Amplatzer™ PFO Occluder.

Current selected region:
UNITED STATES
I'm a patient healthcare professionals
Skip to main content

About the Amplatzer™ PFO Occluder

About device i Stock 930020910

A pioneering device known around the world

Abbott created the PFO occlusion category, and the Amplatzer™ PFO Occluder has sustained leadership over decades of use and was the first device supported by positive trial results.

Hear from a fellow medical professional

We can do better in stroke prevention by using them (Amplatzer PFO) in the appropriate patient.”

— Jeffrey Saver, MD, UCLA Comprehensive Stroke Center
Occluder design 2 hcp 2x

Often imitated, never matched

Industry-leading device.¹
Developed specifically for the treatment of PFO closure.

Device design

  • Percutaneous, transcatheter closure
  • Self-expanding, double-disc design
  • Nitinol wire mesh with polyester fabric/thread
  • Recapturable and repositionable
  • FDA approval in 2016; CE Mark in 1998

Learn more about the PFO closure procedure

Discover how the Amplatzer™ PFO Occluder is implanted through a minimally invasive, same-day, out-patient procedure.

About the procedure
References

† Effective closure
*On commonly used sizes (25mm and 35mm devices)

  1. Internal data. Data on-file at Abbott.
  2. Heinrich P. Mattle, Stefan Evers, David Hildick-Smith, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial, European Heart Journal, Volume 37, Issue 26, 7 July 2016, Pages 2029–2036.
MAT-2002572 v2.0 | Item approved for U.S. use only.